Drug Database
Back to search

Switzerland· 70221002

Lunsumio subkutan 45 mg/1ml, Injektionslösung

A mosunetuzumab product containing mosunetuzumabum, registered in Switzerland by Roche Pharma (Schweiz) AG and dispensed under Swissmedic category A. The same ATC class is registered in 12 of our 19 countries.

Cat A (Swissmedic)ATC L01FX25

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedLunsumio subkutan 45 mg/1ml, Injektio…ATCL01FX25REGISTER NO.70221002PACKS LISTED0CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about mosunetuzumabumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Mosunetuzumab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FX25 (mosunetuzumab), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 7 of them publish a price we can compare per daily dose
Search mosunetuzumab products by name

Mosunetuzumab · ATC L01FX25

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
mosunetuzumabum
Manufacturer
Roche Pharma (Schweiz) AG
Country
Switzerland (CH)
ATC code
L01FX25
ATC class
Mosunetuzumab
Defined daily dose
1.8 mg, P
Swissmedic category
A
Reimbursed
No
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mosunetuzumab in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mosunetuzumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Lunsumio
  • Liechtenstein · Lunsumio
  • Norway · Lunsumio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/31d41574-3569-4ae5-a429-b4a5729c41e4
GET /v1/drugs/31d41574-3569-4ae5-a429-b4a5729c41e4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{}
API referenceMCP serverPlans

See everything about mosunetuzumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console